Zacks Research Has Optimistic Outlook of LLY Q1 Earnings

Eli Lilly and Company (NYSE:LLY - Free Report) - Analysts at Zacks Research lifted their Q1 2026 earnings estimates for shares of Eli Lilly and Company in a note issued to investors on Thursday, April 10th. Zacks Research analyst K. Shah now anticipates that the company will post earnings per share of $6.30 for the quarter, up from their previous forecast of $6.22. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q2 2026 earnings at $7.32 EPS, Q3 2026 earnings at $8.23 EPS, Q4 2026 earnings at $9.44 EPS, FY2026 earnings at $31.28 EPS, Q1 2027 earnings at $7.87 EPS and FY2027 earnings at $39.21 EPS.

LLY has been the subject of a number of other research reports. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price target for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a report on Thursday, January 16th. Truist Financial upped their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Finally, Guggenheim dropped their price target on Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating on the stock in a research note on Monday. Two research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,012.00.

Remove Ads

Eli Lilly and Company Stock Down 2.5 %

Shares of NYSE LLY traded down $19.20 during trading hours on Monday, hitting $737.98. The company had a trading volume of 1,457,652 shares, compared to its average volume of 3,379,772. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm's 50 day moving average is $832.96 and its 200-day moving average is $821.54. The stock has a market capitalization of $699.73 billion, a P/E ratio of 63.02, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%.

Institutional Trading of Eli Lilly and Company

Several large investors have recently modified their holdings of LLY. Vanguard Group Inc. lifted its stake in Eli Lilly and Company by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 74,248,997 shares of the company's stock worth $57,320,226,000 after purchasing an additional 475,530 shares during the last quarter. Geode Capital Management LLC boosted its stake in Eli Lilly and Company by 1.7% in the fourth quarter. Geode Capital Management LLC now owns 17,382,846 shares of the company's stock valued at $13,389,651,000 after buying an additional 291,875 shares in the last quarter. GAMMA Investing LLC boosted its stake in Eli Lilly and Company by 103,831.6% in the first quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after buying an additional 14,852,076 shares in the last quarter. Wellington Management Group LLP grew its position in Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after acquiring an additional 2,012,129 shares during the last quarter. Finally, Norges Bank acquired a new position in Eli Lilly and Company during the fourth quarter worth about $8,407,908,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.